^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 891065

    i
    Other names: BI 891065, BI891065, BI-891065
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    IAP inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours) (clinicaltrials.gov)
    P1, N=12, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    ezabenlimab (BI 754091) • BI 891065
    over4years
    [VIRTUAL] Targeting IAP in cancer: BI 891065 a potent small molecule SMAC mimetic that synergizes with immune checkpoint inhibition (AACR-II 2020)
    The presented data demonstrate the potential of BI 891065 to facilitate tumor cell death and to enhance anti-tumor immune responses, and nominate the compound as an attractive combination partner in cancer therapy. Our results led to the identification of potentially novel modulators of SMAC mimetic sensitivity via genome-wide CRISPR/Cas9 drug sensitizer screens and suggest colorectal cancer as a promising indication for clinical positioning.
    Checkpoint inhibition
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP8 (Caspase 8)
    |
    BI 891065